

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ASCENTAGE PHARMA GROUP INTERNATIONAL**

**亞盛醫藥集團**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6855)**

### **GRANT OF AWARDS UNDER THE RSU SCHEME**

Reference is made to (i) the prospectus of Ascentage Pharma Group International (the “**Company**”, together with its subsidiaries, the “**Group**”) dated October 16, 2019 (the “**Prospectus**”); (ii) the 2019 annual report of the Company dated April 17, 2020; and (iii) the 2020 interim report of the Company dated September 14, 2020 in relation to, among other things, the RSU Scheme of the Company. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

### **GRANT OF AWARDS UNDER THE RSU SCHEME**

The Board hereby announces that, on September 14, 2020, the Company granted 2,333,181 RSUs under the RSU Scheme (the “**Awards**”), representing 2,333,181 Shares to 53 RSU Selected Persons, who are employees of the Group. Shares representing the maximum number of RSUs of the Company that may be granted under the RSU Scheme (being 5,274,657 Shares) were issued and allotted to the RSU Holdco as the settlor of the RSU Scheme prior to the Listing. The vesting of the Awards will be satisfied by such Shares held by the RSU Holdco.

As no new Shares will be issued by the Company pursuant to the grant of the Awards, it will not result in any dilution effect on the shareholdings of existing Shareholders.

To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, the aforementioned RSU Selected Persons are third parties independent of the Company and are not connected persons of the Company, and none of them is a director, chief executive or substantial shareholder of the Company or any of its subsidiaries, or an associate (as defined under the Listing Rules) of any of them as at the date of grant of the Awards.

The Awards shall vest in accordance with the vesting criteria, conditions and time schedule as determined by the Board in its sole and absolute discretion.

## **IMPLICATIONS UNDER THE LISTING RULES**

The RSU Scheme does not involve the grant of options in respect of new shares or other new securities of the Company or any of its subsidiaries, and is therefore not within the scope of, and subject to, Chapter 17 of the Listing Rules.

By order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, People's Republic of China, September 16, 2020

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive Directors.*